Kura Oncology IncKURA
Price$10.65Intrinsic value$12.7219% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $77.2M+43.3% YoYTTM through 30 Jun 2026
Net Income -$296.8MTTM through 30 Jun 2026
Free Cash Flow -$117.4MTTM through 30 Jun 2026

Margins

Current
Gross Margin98.6%
EBITDA Margin-410.5%
Operating Margin-431.5%
Net Margin-384.3%

Returns

-68.0%ROE
-50.5%ROA

Balance Sheet Health

Debt / Equity0.23x
Current Ratio6.06x
Net Debt-$556.5Mnet cash position
Cash & Equivalents$70.2M

Quality Metrics

Altman Z-Score-2.73
Piotroski F-Score3 / 9
FCF Margin-152.1%
Rule of 40-122.6
Earnings-Beat Rate0.0%

Multi-Year Trend

Revenue
'23'24'25
FY2025: $67.5M
Diluted EPS-$3.37TTM
'20'21'22'23'24'25
FY2025: $-3.18

Dividend

No dividend

Capital Allocation

Capex Intensity7.3%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.